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Mesenchymal stem cells (MSCs) have been demonstrated to be useful for cartilage 
tissue regeneration. Bone marrow (BM) and synovial fluid (SF) are promising sources for 
MSCs to be used in cartilage regeneration. In order to improve the clinical outcomes, it 
is recommended that prior to clinical use, the cellular properties and, specifically, their 
chondrogenic potential must be investigated. The purpose of this study is to compare 
and better understand the in vitro chondrogenic potential of equine bone marrow-derived 
mesenchymal stem cells (BMMSCs) and synovial fluid-derived mesenchymal stem cells 
(SFMSCs) populated from the same equine donor. BM- and SF-derived MSCs cultures 
were generated from five equine donors, and the MSCs were evaluated in vitro for their 
morphology, proliferation, trilineage differentiation, and immunophenotyping. Differences 
in their chondrogenic potentials were further evaluated quantitatively using glycosami-
noglycan (GAG) content and via immunofluorescence of chondrogenic differentiation 
protein markers, SRY-type HMG box9, Aggrecan, and collagen II. The BMMSCs and 
SFMSCs were similar in cellular morphology, viability, and immunophenotype, but, varied 
in their chondrogenic potential, and expression of the key chondrogenic proteins. The 
SFMSCs exhibited a significant increase in GAG content compared to the BMMSCs 
(P  <  0.0001) in three donors, suggesting increased levels of chondrogenesis. The 
expression of the key chondrogenic proteins correlated positively with the GAG content, 
suggesting that the differentiation process is dependent on the expression of the target 
proteins in these three donors. Our findings suggest that even though SFMSCs were 
hypothesized to be more chondrogenic relative to BMMSCs, there was considerable 
donor-to-donor variation in the primary cultures of MSCs which can significantly affect 
their downstream application.
Keywords: chondrogenesis, mesenchymal stem cells, bone marrow, synovial fluid, cartilage regeneration, horse
Abbreviations: MSCs, mesenchymal stem cells; BM, bone marrow; SF, synovial fluid; BMMSCs, bone marrow-derived mesen-
chymal stem cells; SFMSCs, synovial fluid-derived mesenchymal stem cells; GAG, glycosaminoglycan; SOX9, SRY-type HMG 
box9; Col II, collagen type II.
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inTrODUcTiOn
Osteoarthritis (OA) is a chronic disease pertaining to progressive 
deterioration of the articular cartilage and subchondral bone (1). 
OA is a major cause of reduced performance and loss in human 
and equine population (2–4). Attempts have been made to treat 
OA and prevent joint degeneration, which primarily includes 
injection of pain relief medications to reduce inflammation and 
treat pain (5). Since, cartilage degeneration is a sequel to OA, 
aggressive surgical approaches such as chondrocyte implantation 
have also been used in the treatment of massive chondral injuries 
in human and equine patients (6, 7). To date, no therapies are 
available to effectively regenerate the affected tissue, posing OA as 
a major health concern. In recent years, mesenchymal stem cells 
(MSCs) have shown promise in human and equine regenerative 
medicine and have been used in tissue regeneration and treat-
ment of many diseases including those affecting the joint (8–12).
Equine adult MSCs are multipotent progenitor cells that can 
be isolated from various adult tissues, including bone marrow 
(BM), adipose tissue (AD), and peripheral blood (13–16). 
Recently, MSCs generated from equine synovial fluid (SF) have 
been shown to be multipotent in vitro (17, 18). Even though MSCs 
can be easily isolated from various sources, researchers have 
reported differences regarding their basic biological properties, 
in  vitro. These differences include proliferation, differentiation, 
and immunomodulatory effect, which can adversely impact their 
function and hence, the in vivo application (19–21). Furthermore, 
variations or differences can occur in the properties of MSCs 
generated not only from different sources but also from the same 
source in different donors. For instance, we reported a study 
where we observed differences within bone marrow-derived 
mesenchymal stem cells (BMMSCs) in a group of age- and 
gender-matched horses (22).
Bone marrow is an acceptable adult stem cell source used 
in cartilage tissue engineering (23, 24). However, possible 
contamination during BM aspiration, decrease in proliferation 
and chondrogenic potential with age, hypertrophy, and miner-
alization when implanted in vivo hinder its clinical application 
(25). Hence, BMMSCs may not be the best source for cartilage 
repair. Recently, it has been recognized in both human and equine 
medicine that SF collection is relatively easy, less invasive, and a 
rich source of MSCs. In addition, the synovial MSCs have greater 
proliferative and chondrogenic abilities than other MSCs, mak-
ing SF or the synovium cells as an alternative, accessible source 
of MSCs and a suitable candidate for cartilage repair (17, 26, 27).
Although BM and SF represent attractive tissue sources 
for MSCs, there has been no comparison of the chondrogenic 
potential of these cells from the same donor. Based on published 
papers and the results from our laboratory, we hypothesize that 
equine synovial fluid-derived mesenchymal stem cells (SFMSCs) 
can be isolated and characterized in vitro and their chondrocyte 
differentiation would be superior to BMMSCs, but there may be 
donor-to-donor variations when donor-matched comparison is 
done. In order to prove our hypothesis, we performed a donor-
matched comparison of the biological properties of equine MSCs 
isolated from BM and SF. Differences, if any, in their chondrogenic 
potentials were evaluated using glycosaminoglycan (GAG) assay 
and by assessing changes in the key proteins of chondrogenic 
differentiation using immunofluorescence (IF).
MaTerials anD MeThODs
Tissue harvest and isolation of Mscs
All the experiments were conducted in accordance with the pro-
tocols approved by University of Tennessee Institutional Animal 
Care and Use Committee. Five healthy, mixed breed horses, aged 
8–13 years were used for BM and SF collections.
Bone Marrow
All procedures were performed as described previously (22, 28). 
Mononuclear fraction of cells from BM (n = 5) collected in the 
presence of 100  IU/ml heparin (Celsus, Cincinnati, OH, USA) 
were seeded in the basal medium consisting of Dulbecco’s Modified 
Eagle Medium/Ham’s F-12 (Fisher Scientific, Pittsburgh, PA, 
USA), 10% fetal bovine serum (Merck Animal Health, Summit, 
NJ, USA), and 1% penicillin/streptomycin solution (Fisher 
Scientific, Pittsburgh, PA, USA) and incubated at 37°C, with 5% 
CO2 (Fisher Scientific, Pittsburgh, PA, USA). Adherent cells were 
allowed to reach 70–80% confluency before being harvested with 
0.25% trypsin EDTA (Fisher Scientific, Pittsburgh, PA, USA) for 
2 min at 37°C.
Synovial Fluid
Synovial fluid (n =  5) was obtained using methods described 
previously (17, 18) with slight modifications. Horses were 
sedated with detomidine HCl (Pfizer Animal Health, NY, USA) 
(0.015–0.26 mg/kg bwt i.v.), 2–5 ml of SF was collected aseptically 
from each of the radiocarpal, intercarpal, and tarsocrural joints. 
Approximately 0.5 ml of each sample was collected in microtainer 
tubes containing EDTA (Fisher Scientific, Pittsburgh, PA, USA) 
and was analyzed for cytology. For proliferation and expansion 
of SFMSCs from confirmed clinically normal SF, 1 ml of SF was 
diluted (1:10) with DMEM F-12 (Fisher Scientific, Pittsburgh, PA, 
USA) basal medium and seeded onto 75 cm2 vented tissue culture 
flasks (Fisher Scientific, Pittsburgh, PA, USA) and incubated at 
37°C, with 5% CO2 (Fisher Scientific, Pittsburgh, PA, USA) for 
4 days before the first medium change. Thereafter, medium was 
changed every 2–3 days until the cells reached 70–80% conflu-
ency. Adherent cells were harvested with 0.25% trypsin EDTA 
(Fisher Scientific, Pittsburgh, PA, USA) for 1 min at 37°C.
Each horse was sampled twice between 3 and 6 months. All the 
cell culture experiments were carried out in triplicate, and each 
assay was repeated with the equine MSCs from two independent 
BM and SF harvests.
nuclear/cytoplasmic staining
Nuclear/cytoplasmic fluorescent staining was used to demon-
strate the morphology of MSCs for cytoplasmic staining; MSCs 
were stained with 5  µg of WGA (Life Technologies, Grand 
Island, NY, USA) (wheat germ agglutinin, Alexa Fluor 488 
conjugate) for 10  min. To stain the nucleus, cells were further 
washed and stained with 5  µg of TO-PRO-3 iodide stain (Life 
Technologies, Grand Island, NY, USA) for 10 min. After washing, 
the cells were mounted with Slow Fade Gold Antifade Reagent 
TaBle 1 | antibodies used for analyzing the specific molecular markers 
on the cell surface.
Protein marker clone Dilution Form
CD90 OX-7 1:10 Fluorescein 
isothiocyanate (FITC) 
conjugate
CD34 581 1:5 FITC conjugate
CD29 4B4LDC9LDH8 1:5 FITC conjugate
CD44 IM7 1:100 Non-conjugate
Major histocompatibility 
complex II monomorphic
CVS20 1:10 FITC conjugate
Secondary (FITC) – 1:100 Alexa Fluor 488 anti-rat
Isotype control (IgG1) A85-1 1:10 FITC conjugate
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(Life Technologies, Grand Island, NY, USA), and images were 
obtained using a laser scanning spectral confocal microscope 
(Leica Microsystems©, Wetzlar, Germany).
cell Viability and Proliferation
The cellular viability and proliferation of 2.0 × 104 cells of P2–P3 
of expanded equine BMMSCs and SFMSCs from each donor 
(n = 5) was assessed at 2, 4, and 8 days using the CellTiter 96 
Aqueous Non-Radioactive (MTS) assay (Promega, Madison, WI, 
USA), as described previously (20, 22). The optical density of the 
cell and the MTS reagent complex was measured on a microplate 
fluorescence reader (BioTek, Winooski, VT, USA) at 490  nm. 
Medium without cells was used as a blank. Graph of absorbance 
at 490 nm vs. days of proliferation was generated.
immunophenotyping
Flow cytometric analysis was performed in P2–P3 expanded 
BMMSCs and SFMSCs from each donor (n = 5) using a panel 
of cluster-of-differentiation (CD) antigen antibodies. Briefly, for 
each staining, 1 × 106 cells were harvested and collected in 1× 
florescence-activated cell sorting (FACS) buffer (phosphate-buff-
ered saline with 0.1% bovine serum albumin) (Fisher Scientific, 
Pittsburgh, PA, USA). The Fc receptors were blocked by preincu-
bating cells with 0.5 mg/ml mouse (BD Bioscience, Grand Island, 
NY, USA) Fc block for 20 min on ice. After repeated washing, cells 
were incubated with fluorescein isothiocyanate (FITC) precon-
jugated CD90 (BD Bioscience, Grand Island, NY, USA), CD29 
(Beckman Coulter, Brea, CA, USA), CD34 (Millipore, Billerica, 
MA, USA), major histocompatibility complex II (MHC-II) 
(AbD Serotec, Raleigh, NC, USA), and non-conjugated CD44 
(Abcam, Cambridge, MI, USA) primary antibodies for 60 min 
in the dark on ice. To detect CD44, cells were stained with the 
secondary antibody for 30 min on ice (Table 1). Negative control 
staining was performed using a FITC conjugated mouse IgG1 
(BD Bioscience, Grand Island, NY, USA) isotype. The raw data 
of fluorescence were measured using the BD FACS Diva software 
(BD Bioscience, Grand Island, NY, USA). The percentages of cells 
positive for a given protein were recorded.
adipogenesis and Osteogenesis
Roughly, 2.0  ×  105 BMMSCs and SFMSCs from each donor 
(n =  5) were induced to adipogenesis and osteogenesis. Cells 
were seeded in tissue culture dishes in the basal medium, with 
the medium change every 2–3 days. At 70–80% confluency, cells 
were induced to differentiate into each of the two lineages using 
lineage-specific differentiation media. Adipogenic differentiation 
was induced in complete growth medium supplemented with 
1 µmol/l dexamethasone (BioTek, Winooski, VT, USA), 10 µg/
ml recombinant human insulin (BioTek, Winooski, VT, USA), 
0.5  mmol/l 3-isobutyl-1-methylxanthine (BioTek, Winooski, 
VT, USA), 15% rabbit serum (BioTek, Winooski, VT, USA), 
and 20  µmol/l indomethacin (BioTek, Winooski, VT, USA). 
Osteogenic differentiation was induced in complete growth 
medium supplemented with 100  nmol/l dexamethasone, 
10  mmol/l β-glycerophosphate (BioTek, Winooski, VT, USA), 
and 0.25  mmol/l ascorbic acid (BioTek, Winooski, VT, USA). 
Adipogenic and osteogenic differentiation was confirmed at day 
7 and 14 using 0.5% Oil Red O staining and 2% Alizarin Red 
S staining (Fisher Scientific, Pittsburgh, PA, USA), respectively. 
Stained cells were visualized and photographed using Nikon 
DS-Fi2 connected to a Zeiss microscope and evaluated using the 
NIS Elements imaging software (BioTek, Winooski, VT, USA).
chondrogenesis and gag content
A total of 70–80% confluent 2.0 × 105 BMMSCs and SFMSCs from 
each donor (n = 5) were induced to chondrogenic differentiation. 
Differentiation was induced using complete growth medium 
supplemented with 100  nmol/l dexamethasone, 0.25  mmol/l 
ascorbic acid (Sigma-Aldrich, Saint Louis, MI, USA), and 5 ng/ml 
transforming growth factor beta (R&D Systems, Minneapolis, 
MI, USA) for 14 days. To confirm chondrogenic differentiation, 
cells were stained with Alcian Blue (pH = 2.5) (Fisher Scientific, 
Pittsburgh, PA, USA). To measure the GAG content, subsequent 
to staining, Alcian Blue dye was extracted by exposing the cells 
to 500 µl of 6M guanidine/HCl (Fisher Scientific, Pittsburgh, PA, 
USA) overnight with shaking at room temperature. The optical 
density of the extracted Alcian Blue was measured on a microplate 
fluorescence reader (BioTek, Winooski, VT, USA) at 620 nm.
iF staining
Bone marrow-derived mesenchymal stem cells and SFMSCs 
from each donor (n = 5) were cultured as described above until 
70–80% confluent and were subsequently induced to differentiate 
into chondrocytes using the cocktail described above for 14 days. 
Differentiated cells were fixed with 4% paraformaldehyde for 
10 min, permeabilized with 0.1% Triton X-100 (Sigma-Aldrich, 
Saint Louis, MI, USA) for 10 min, and finally blocked with 1% 
Power Block (BioGenex, San Ramon, CA, USA) for 30  min. 
For each analysis, SRY-type HMG box9 (SOX9) (Santa Cruz 
Biotechnology, Dallas, TX, USA), Aggrecan (Fisher Scientific, 
Pittsburgh, PA, USA), and collagen type II (Col II) (Abcam, 
Cambridge, MI, USA) were used to detect the target proteins 
(Table  2). Antigen detection was performed using specific 
secondary antibodies. Samples were mounted in Prolong Gold 
antifade reagent with DAPI (Life Technologies, Grand Island, NY, 
USA), and images were obtained with a laser scanning spectral 
confocal microscope (Leica Microsystems©, Wetzlar, Germany). 
Fluorescent-labeled secondary antibodies alone and FITC-
labeled anti-mouse immunoglobulin G1 were used as negative 
FigUre 2 | Measurement of cell proliferation of bone marrow-derived 
mesenchymal stem cells (BMMscs) and synovial fluid-derived 
mesenchymal stem cells (sFMscs). MTS assay was used to evaluate the 
rate of proliferation over a period of 8 days. Absorbance, optical density at 
490 nm is linearly related to the cell numbers and hence represents the 
proliferation at a given time point. Increase in the optical density between two 
time points can be used as an index to measure the rate of proliferation. Data 
are presented as means ± SD. Error bars represent the SD.
FigUre 1 | nuclear/cytoplasmic staining of mesenchymal stem cells. 
Representative confocal images of WGA (green) and TOPRO-3-iodide (red) 
fluorescent stains showing the viability and morphology of the cells.  
(a) Typical fibroblast-like morphology of undifferentiated bone marrow-
derived mesenchymal stem cells. (B) Typical fibroblast-like morphology of 
undifferentiated synovial fluid-derived mesenchymal stem cells. Scale 
bar = 100 µm.
TaBle 2 | Differentiation time, dilution, and secondary antibodies for chondrogenic protein markers using immunofluorescence analysis.
Protein marker Differentiation day Dilution concentration (µg/ml) secondary antibody
SRY-type HMG box9 3 1:100 2 Alexa fluor 647 anti-rabbit
Aggrecan 14 1:200 4 Alexa Fluor 488 anti-mouse
Collagen type II 14 1:200 4 Alexa Fluor 488 anti-rabbit
4
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controls. Mean intensity fluorescence was quantified using the 
Leica TCS SP2 software by selecting at least four representative 
areas of the same settings.
statistical analysis
For the statistical analysis, all quantitative group data are shown 
as the mean ±  SD. Data for cell proliferation, GAG content, 
immunophenotyping, and IF from the two cell sources were 
analyzed and compared using Student’s t-test (SPSS version 23, 
SPSS, Chicago, IL, USA). Differences of P < 0.05 were considered 
to be statistically significant.
resUlTs
isolation and In Vitro expansion of Mscs
Bone marrow-derived mesenchymal stem cells adhered to the 
tissue culture polystyrene-treated plastic within 48  h from 
seeding, proliferated, and maintained spindle-like morphology 
throughout the expansion process. The SFMSCs were rounded 
when seeded in culture, acquired spindle-like morphology 
within 4  days after seeding, proliferated, and maintained 
spindle-like morphology throughout the expansion process. 
The cellular morphology was monitored and observed up to 
passage 6 for both cell types. The morphology was confirmed 
using a standard nuclear/cytoplasmic fluorescent staining 
(Figures 1A,B).
cell Proliferation and Viability
Cellular proliferation and viability of BMMSCs and SFMSCs were 
assessed through a period of 8 days using MTS assay (Figure 2). 
In presence of the growth medium provided, both cell types were 
viable and the cell numbers increased linearly over time, suggest-
ing that both types of MSCs can be expanded in vitro to generate 
sufficient numbers for implantation.
immunophenotyping
Flow cytometric analyses of BMMSCs and SFMSCs from all 
donors, revealed >70% expression of MSCs markers including 
CD29, CD44, and CD90. The BMMSCs were negative for CD34, a 
hematopoietic marker, and MHC-II. Comparatively, the SFMSCs 
exhibited low levels of CD34 and significantly high expression 
of MHC-II. The average percentage of each marker with SD is 
illustrated in Table 3.
adipogenesis and Osteogenesis
Subjective evaluation of the patterns of differentiation demon-
strated that both BMMSCs and SFMSCs undergo differentiation 
in presence of the lineage-specific induction media. The adipo-
genic and osteogenic differentiation was demonstrated by the 
deposition of lipid droplets into the cytoplasm, as visualized 
by Oil Red O staining and calcium matrix precipitation using 
alizarin red dye, respectively (Figure 3).
FigUre 3 | representative images of adipogenic and osteogenic differentiation assays. Bone marrow-derived mesenchymal stem cells (BMMSCs) and 
synovial fluid-derived mesenchymal stem cells (SFMSCs) were induced to differentiate using lineage-specific media. (a,B) Oil Red O staining of cells cultured for 
7 days in undifferentiated and adipogenic differentiation medium, respectively. (c,D) Alizarin red staining of cells cultured for 14 days in undifferentiated and 
osteogenic differentiation medium, respectively. Scale bar = 100 μm.
TaBle 3 | Percentage means of mesenchymal stem cells (Mscs) from bone marrow (BM) and synovial fluid (sF) of the same donor for the cD90, cD29, 
cD44, cD34, and major histocompatibility complex ii (Mhc-ii) markers by flow cytometry.
Donors cD90 cD29 cD44 cD34 Mhc-ii
Bone marrow-derived mesenchymal stem cells (BMMSCs) donor 1 95.55 ± 0.55 75.6 ± 3 96.6 ± 0 1.15 ± 0.85 0.28 ± 0
Synovial fluid-derived mesenchymal stem cells (SFMSCs) donor 1 83.35 ± 2.35 90.55 ± 1.65 91.5 ± 4.5 0.95 ± 0.75 3.245 ± 2.65
BMMSCs donor 2 90.95 ± 4.35 65.95 ± 7.3 99.1 ± 0 1.05 ± 0.05 1.36 ± 0.36
SFMSCs donor 2 76.3 ± 6 71.55 ± 6.75 94.25 ± 1.25 1.45 ± 0.35 7.805 ± 5.1
BMMSCs donor 3 97.25 ± 2.55 86.35 ± 12.15 92.65 ± 7.3 0.635 ± 0.36 1.85 ± 0.45
SFMSCs donor 3 98.9 ± 0.5 99.75 ± 0.25 99.9 ± 0 10.25 ± 0.25 10.2 ± 0.8
BMMSCs donor 4 86.15 ± 0.65 98.8 ± 0.85 99.9 ± 0.1 0.15 ± 0.05 1.75 ± 0.65
SFMSCs donor 4 95.3 ± 0.1 98.8 ± 0.8 99.4 ± 0.4 1.72 ± 0.02 6.15 ± 1.4
BMMSCs donor 5 99.9 ± 0.05 99.6 ± 0.1 99.8 ± 0 3.5 ± 0.3 4.1 ± 0.9
SFMSCs donor 5 96.4 ± 2.8 99.4 ± 0.1 99.7 ± 0.05 0.99 ± 0.5 21 ± 6
5
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chondrogenesis
Chondrogenic differentiation was demonstrated by the deposi-
tion of GAG by Alcian Blue staining. Striking differences were 
observed, these differences in staining were supported by the 
variations in the GAG content in each of the differentiated sample 
(Figure 4).
The GAG content was measured and compared between the 
BMMSCs and SFMSCs within each donor. SFMSCs of three 
donors exhibited a significant increase in GAG content com-
pared to the BMMSCs (P <  0.0001–0.006). Other two donors, 
the pattern was reversed and the BMMSCs exhibited a significant 
increase (P <  0.0001–0.003) in GAG content compared to the 
SFMSCs (Figure 4).
The variations in chondrogenesis were further evaluated by 
assessing the expression of chondrogenic protein markers dur-
ing differentiation. IF demonstrated the expression of SOX9, 
Aggrecan, and Col II at 3, 14, and 14 days, respectively, in both cell 
types (Figures 5 and 6). However, quantitative analyses showed 
significant variation in their expression levels. The expression 
levels of all three target proteins were significantly upregulated 
in SFMSCs compared to BMMSCs from at least two donors. 
Aggrecan was the only protein marker that was significantly 
upregulated in BMMSCs cultured from two donors.
DiscUssiOn
Effective cartilage tissue engineering using MSCs mostly depends 
on the capacity of cells to proliferate, differentiate, and establish 
cartilage in  vivo. BM and AD have been the most extensively 
studied and used sources for obtaining MSCs. To alleviate some 
of the technical challenges associated with the tissue harvest and 
properties of MSCs cultured ex vivo from BM and AD, recently, 
SF and the synovium membrane have been identified as alterna-
tive sources.
Reports have demonstrated that SFMSCs are multipotent 
and exhibit properties of adult MSCs; in addition, SF collection 
is relatively easy and less invasive (17, 18, 26, 29). Studies have 
reported the isolation, identification, and biological properties 
of equine SFMSCs and BMMSCs (17, 18, 23, 30). However, 
a detailed pairwise comparison with respect to the growth, 
FigUre 5 | representative images to show the expression of cartilage-specific protein marker (srY-type hMg box9; sOX9) detected by 
immunofluorescence in cultured bone marrow-derived mesenchymal stem cell (BMMscs) and synovial fluid-derived mesenchymal stem cell 
(sFMscs) from one donor. (a) Cells were stained for SOX9 (red) and DAPI (blue). (B) Quantitation of SOX9 expression in BMMSCs and SFMSCs. Results are 
significantly different (*P < 0.004). Scale bar = 100 μm.
FigUre 4 | representative images of chondrogenic differentiation assays. Bone marrow-derived mesenchymal stem cell (BMMSCs) and synovial 
fluid-derived mesenchymal stem cells (SFMSCs) were induced to differentiate using transforming growth factor beta containing media. (a,B) Alcian Blue staining of 
undifferentiated and differentiated BMMSCs, respectively, cultured for 14 days. (c,D) Alcian Blue staining of undifferentiated and differentiated SFMSCs, respectively, 
cultured for 14 days. Scale bar = 100 μm. (e) Quantative analyses of glycosaminoglycan (GAG) contents of differentiated BMMSCs and SFMSCs by GAG assay at 
day 14. Data are presented as means ± SD. Error bars represent the SD. Results are significantly different (*P < 0.001).
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chondrogenic differentiation, and expression of chondrogenic 
proteins between BMMSCs and SFMSCs from the same donor 
has not been reported. The impact of donor is particularly critical 
for autologous treatment regimens and in deciding whether such 
a cell-based therapy represents the appropriate treatment option 
for an individual patient. Thus, the purpose of this study was to 
investigate in vitro properties of SFMSCs and BMMSCs generated 
from five donors with a focus on their cartilage forming potential.
In this study, MSCs adhered to tissue culture flasks and prolifer-
ated showing spindle, fibroblast-like morphology that is typical of 
MSCs. SF harvested from a joint has limited number of progenitor 
cells and hence requires in vitro expansion to generate sufficient 
numbers of viable MSCs required for the treatment of an injury 
(18, 31). A linear increase in both BMMSCs and SFMSCs from 
five equine donors over a period of 8 days (Figure 2), suggested 
that in presence of an optimal growth medium containing 10% 
fetal bovine serum, both BMMSCs and SFMSCs are viable and 
can generate sufficient numbers of MSCs for clinical application 
(27). Similar expression levels of the three commonly reported 
CD markers, CD29, CD44, and CD90, in BMMSCs and SFMSCs 
(Table  3) from all donors further confirmed the “stemness” 
of these primary cultures. Most importantly, the high level of 
7Zayed et al. Chondrogenesis of Equine Stem Cells
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MHC-II expression suggests that in contrast to the BMMSCs, 
the SFMSCs may not be used as an allogeneic source of MSCs for 
therapy; however, in vivo investigation is needed.
The potential for trilineage differentiation is yet another 
important biological property that should always be used to verify 
the multipotentiality of MSCs. Differences have been reported in 
these assays in MSCs derived from various sources (14, 19, 30, 
32). Consistent with the previous studies, cells from both sources 
differentiated into adipocytes, osteocytes, and chondrocytes 
within 7, 14, and 14 days, respectively (14, 18, 32). Of relevance 
to this study, even though both BMMSCs and SFMSCs from all 
donors showed the potency to differentiate into chondrogenic 
lineage, the process exhibited varying degrees. Subjectively, 
the Alcian Blue staining and quantitatively measured by GAG 
content, there was a significant upregulation in the chondrogenic 
potentials of SFMSCs from three out of five donors (Figure 4). 
On the other hand, the chondrogenic potential of BMMSCs from 
two donors were upregulated relative to SFMSCs. Thus, results 
suggest that all SFMSCs are not necessarily superior to BMMSCs 
in their chondrogenic potential but demonstrate donor-to-donor 
variation.
Mesenchymal cell differentiation into chondrocytes is a 
complex process that involves a very well-orchestrated signaling 
pathway of growth factors (33). In our study, we investigated the 
changes in expression of specific key markers that coordinate 
this process in the hope of understanding what makes one MSC 
culture better suited for chondrogenesis compared to the other. It 
has been shown that SOX9, a master regulatory factor, regulates 
a specific set of genes in chondrocytes (34, 35). Aggrecan and Col 
II are the major components in the articular cartilage, which play 
an important role in chondrocytes differentiation and chondro-
cyte–matrix interactions (36, 37). Col II is an important marker 
for hyaline cartilage, which is valuable when cartilage healing is 
evaluated in vivo. Our results indicate that both BMMSCs and 
SFMSCs could express SOX9, Aggrecan, and Col II in all primary 
cultures, however, with varying levels.
The significant upregulation of SOX9 in SFMSCs cultured 
from two donors, along with a significantly higher GAG content 
and Aggrecan, suggests that the increased levels of these regula-
tory proteins may be responsible for their higher chondrogenic 
potential. Additionally, the significant upregulation of Col II in 
SFMSCs from three donors suggests that the potential for regen-
eration of hyaline cartilage is higher in these SFMSCs (Figure 6). 
Conversely, BMMSCs from other two donors demonstrate 
significant increase in GAG content coupled with the expression 
of Aggrecan, but there is no change in the SOX9 expression 
FigUre 6 | representative images to show the expression of cartilage-specific protein markers detected by immunofluorescence in cultured bone 
marrow-derived mesenchymal stem cell (BMMscs) and synovial fluid-derived mesenchymal stem cell (sFMscs) from one donor. (a) Cells were 
stained for Aggrecan (green) and DAPI (blue). (B) Cells were stained for collagen type II (Col II) (green) and DAPI (blue). Quantitation of chondrogenic protein markers, 
Aggrecan (c) and Col II (D), respectively, expression in BMMSCs and SFMSCs. Results are significantly different (*P < 0.004). Scale bar = 100 μm.
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